Thu.May 21, 2020

article thumbnail

Adapting Clinical Trial Protocol in Response to COVID-19

VirTrial

Based on recent SCRS survey data , a vast majority of research sites (58%) anticipate that COVID-19 will negatively affect their clinical trial enrollment and nearly half of respondents (47%) feel COVID-19 will have a negative effect on retention. With the number of new cases increasing daily, these expectations are, unfortunately, likely to be correct. .

article thumbnail

Why Do CVS And Express Scripts Rely on Secretive Private Companies to Run Their Copay Maximizer Programs?

Drug Channels

In Copay Maximizers Are Displacing Accumulators—But CMS Ignores How Payers Leverage Patient Support , I explained a new Centers for Medicare and Medicaid Services (CMS) final rule regarding health plans’ use of copay accumulator adjustment. I also highlighted why plans have responded to the negative patient impact from accumulators with copay maximizer programs.

Drugs 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Clinical Trial Budget & Payment Management Solution Overview

Cloudbyz

[link]. Cloudbyz Budget management solution is an integrated end-to-end solution that enables all the stakeholders, ie Sponsors, CRO’s and Sites to gain visibility, control and flexibility in managing the financials across clinical trial projects. The solution helps in accelerating study budget management with a high level of accuracy and minimal manual effort.

article thumbnail

Update on COVID-19

Pharma Packaging Solutions

As the situation with COVID-19 continues to change, we wanted to let you know that Carton Service/Pharma Packaging Solutions is defined as an Essential Industry due to the life-sustaining products we produce. Even with communities establishing Shelter-In-Place or Safer-At-Home orders, our associates have been notified that they are essential workers.

article thumbnail

Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

article thumbnail

Community means the world to ClientPharma

Client Pharma

Client-Pharma is committed to providing a first-class service to clients all over the world, and closer to home they pledged to serve the local community that emulates their core company values. Since the UK lock-down began, Client-Pharma teamed up with a local restaurant to provide fresh hot meals daily for neighborhoods in a local town close to the office HQ.

article thumbnail

Amphista Therapeutics appoints leading protein degradation pioneer, Ian Churcher as CSO

Drug Discovery Today

Glasgow, Scotland, 21 May 2020 - Amphista Therapeutics, a biopharmaceutical company creating first-in-class cancer therapeutics that harness the body’s natural processes to remove disease causing proteins selectively and efficiently, today announced the appointment of Dr Ian Churcher as Chief Scientific Officer (CSO).

Protein 40

More Trending

article thumbnail

Our Commitment To You During COVID-19

Pharma Packaging Solutions

We are monitoring the COVID-19 situation very closely. We are confident we can abide by any imposed guidelines while continuing to seamlessly support our customers’ business operations. Because we care about our associates, our customers and our communities, we want to share the steps we are taking during this fluid and changing situation. We do have an active business continuity plan to keep our customers, our visitors, our associates and their families safe and healthy.

article thumbnail

NanoMab Enters into Agreement with University Hospital Aachen to initiate a Cancer Therapy Programme utilising next generation NM-02 radiopharmaceutical product.

Drug Discovery Today

Translational Programme established for FIH late stage HER2 positive breast cancer in Q4 2020